Michael Boyer

50.3k total citations · 9 hit papers
326 papers, 19.7k citations indexed

About

Michael Boyer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Michael Boyer has authored 326 papers receiving a total of 19.7k indexed citations (citations by other indexed papers that have themselves been cited), including 183 papers in Oncology, 175 papers in Pulmonary and Respiratory Medicine and 60 papers in Molecular Biology. Recurrent topics in Michael Boyer's work include Lung Cancer Treatments and Mutations (124 papers), Lung Cancer Research Studies (62 papers) and Lung Cancer Diagnosis and Treatment (47 papers). Michael Boyer is often cited by papers focused on Lung Cancer Treatments and Mutations (124 papers), Lung Cancer Research Studies (62 papers) and Lung Cancer Diagnosis and Treatment (47 papers). Michael Boyer collaborates with scholars based in Australia, United States and Canada. Michael Boyer's co-authors include Kevin Skadron, Shuai Che, Jeremy W. Sheaffer, David Tarjan, Jiayuan Meng, Sangha Lee, U. Gatzemeier, Stephen Clarke, James T. Symanowski and E. Kaukel and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Michael Boyer

318 papers receiving 19.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

2013 2.5k citations Lecia V. Sequist, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

2003 2.3k citations Nicholas J. Vogelzang, James J. Rusthoven et al. Journal of Clinical Oncology profile →
Rodinia: A benchmark suite for heterogeneous computing

2009 2.2k citations Michael Boyer et al. profile →
The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients

2000 768 citations Michael Boyer et al. Journal of Clinical Oncology profile →
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

2017 539 citations Nick Pavlakis, Michael Boyer et al. profile →
A performance study of general-purpose applications on graphics processors using CUDA

2008 451 citations Michael Boyer et al. profile →
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

2017 398 citations Luis Paz‐Ares, Kenneth J. O’Byrne et al. Annals of Oncology profile →
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

2021 201 citations Michael Boyer, Wu‐Chou Su et al. profile →
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

2021 165 citations Michael Boyer, Mehmet Alı Nahıt Şendur et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Michael Boyer	9.1k	8.3k	3.7k	2.5k	2.3k	326	19.7k
Steven Swanson	6.6k 0.7×	1.4k 0.2×	476 0.1×	4.0k 1.6×	5.1k 2.3×	323	14.4k
R. Steele	3.7k 0.4×	9.6k 1.2×	1.9k 0.5×	22 0.0×	1.7k 0.8×	620	20.2k
Wei Zhang	1.8k 0.2×	2.1k 0.2×	5.2k 1.4×	56 0.0×	195 0.1×	612	12.9k
David R. Webb	1.2k 0.1×	832 0.1×	2.2k 0.6×	180 0.1×	264 0.1×	339	11.3k
John B. Little	6.0k 0.7×	4.2k 0.5×	9.1k 2.5×	51 0.0×	171 0.1×	455	23.7k
Josep Roca	11.3k 1.2×	591 0.1×	1.4k 0.4×	82 0.0×	113 0.1×	420	18.6k
Peter E. Clark	4.7k 0.5×	1.8k 0.2×	3.4k 0.9×	12 0.0×	152 0.1×	420	14.4k
Xuan Dong	1.3k 0.1×	2.2k 0.3×	1.1k 0.3×	17 0.0×	737 0.3×	102	16.3k
David S. Alberts	2.8k 0.3×	8.0k 1.0×	6.6k 1.8×	9 0.0×	145 0.1×	573	26.9k
Tim Harris	366 0.0×	260 0.0×	721 0.2×	4.7k 1.9×	9.2k 4.1×	246	13.8k

Countries citing papers authored by Michael Boyer

Since Specialization

Citations

This map shows the geographic impact of Michael Boyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Boyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Boyer more than expected).

Fields of papers citing papers by Michael Boyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Boyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Boyer. The network helps show where Michael Boyer may publish in the future.

Co-authorship network of co-authors of Michael Boyer

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Boyer. A scholar is included among the top collaborators of Michael Boyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Boyer. Michael Boyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wermke, Martin, Sally C. M. Lau, Kelly G. Paulson, et al.. (2025). 2757O Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study. Annals of Oncology. 36. S1366–S1366.

Khoo, Alan Soo Beng, et al.. (2024). Human Papilloma Virus Positive Oropharyngeal Squamous Cell Carcinoma and the Immune System: Pathogenesis, Immunotherapy and Future Perspectives. International Journal of Molecular Sciences. 25(5). 2798–2798. 4 indexed citations

Boyer, Michael, Rina Hui, Philip R. Clingan, et al.. (2024). Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study. BMC Cancer. 23(S1). 1250–1250. 5 indexed citations

Dowlati, Afshin, Horst-Dieter Hummel, Stéphane Champiat, et al.. (2024). Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update. Journal of Clinical Oncology. 42(29). 3392–3399. 22 indexed citations

Brown, Bernadette, et al.. (2023). Clinicians’ Evaluation of Lung Cancer Clinical Quality Indicators and Comparative Performance Data in Practice. European Journal of Cancer Care. 2023. 1–11. 1 indexed citations

Pal, Abhijit, Adnan Nagrial, Jenny Lee, et al.. (2023). Influence of EGFR mutation status and PD‐L1 expression in stage III unresectable non‐small cell lung cancer treated with chemoradiation and consolidation durvalumab. Asia-Pacific Journal of Clinical Oncology. 20(1). 16–24. 4 indexed citations

O’Connor, Claire, Roslyn G. Poulos, Anurag Sharma, et al.. (2023). An Australian aged care home for people subject to homelessness: health, wellbeing and cost–benefit. BMC Geriatrics. 23(1). 253–253. 5 indexed citations

Nguyễn, Thành Vinh, et al.. (2023). Personalised Medicine and the Potential Role of Electrospinning for Targeted Immunotherapeutics in Head and Neck Cancer. Nanomaterials. 14(1). 6–6. 3 indexed citations

Vogelzang, Nicholas J., James J. Rusthoven, James T. Symanowski, et al.. (2023). Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma. Journal of Clinical Oncology. 41(12). 2125–2133. 18 indexed citations

10.

Boyer, Michael, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu, et al.. (2021). Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. Journal of Clinical Oncology. 39(21). 2327–2338. 165 indexed citations breakdown →

11.

Boyer, Michael, et al.. (2021). A Digital Coaching Intervention for Cancer Survivors With Job Loss: Retrospective Study. JMIR Cancer. 7(4). e31966–e31966. 6 indexed citations

12.

Satgunaseelan, Laveniya, Sean Porazinski, Dario Strbenac, et al.. (2021). Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of EGFR Amplification: Implications for Novel Personalized Therapy. Frontiers in Oncology. 11. 750852–750852. 18 indexed citations

13.

Blinman, Prunella, et al.. (2018). Understanding Immune Tolerance of Cancer: Re‐Purposing Insights from Fetal Allografts and Microbes. BioEssays. 40(8). e1800050–e1800050. 7 indexed citations

14.

Lum, Trina, Carsten E. Palme, Bruce Ashford, et al.. (2017). PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma. Pathology. 49(5). 499–505. 41 indexed citations

15.

Sequist, Lecia V., James Chih‐Hsin Yang, Nobuyuki Yamamoto, et al.. (2013). Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology. 31(27). 3327–3334. 2461 indexed citations breakdown →

16.

Oh, Byeongsang, Phyllis Butow, Barbara Mullan, et al.. (2010). Patient-doctor communication: use of complementary and alternative medicine by adult patients with cancer.. eSpace (Curtin University). 8(2). 56–64. 33 indexed citations

17.

Lee, Brian Y., David A. Brown, Mark P. Molloy, et al.. (2009). Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling. Cancer Research. 69(19). 7696–7703. 86 indexed citations

18.

Pezaro, Carmel, Mark Rosenthal, Howard Gurney, et al.. (2009). An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer. American Journal of Clinical Oncology. 32(4). 338–341. 42 indexed citations

19.

Boyer, Michael. (2001). Diagnosis and treatment of testicular cancer. 42(5). 25–29. 1 indexed citations

20.

Boyer, Michael, et al.. (1984). Technique de dosage du céfotaxime et du desacétyl-céfotaxime dans le sérum par chromatographie liquide haute performance.. 32(4). 285–288. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact